Patterns of late gadolinium enhancement in Duchenne muscular dystrophy carriers

Table 4 CMR data in controls and in asymptomatic versus symptomatic Duchenne carriers

Variables	Controls	Asymptomatic	Between DMDc p<	Symptomatic	F	p<
	(n = 37)	(n = 21)		(n = 9)
LGE quantity (ml)	0	0.76 ± 0.17	0.05	1.77 ± 0.27	19.6	0.0001
Percent LGE versus LV mass (%)	0	0.68 ± 0.17	0.02	1.86 ± 0.26	22.1	0.0001
LGE location
Sub-endocardial	0	0	-	0	-
Mid-myocardial	0	0.14 ± 0.05	0.02	0.56 ± 0.09	15.1	0.0001
Sub-epicardial	0	0.33 ± 0.07	0.57	0.44 ± 0.11	10.7	0.0001
Topographic distribution
Segment 4	0	0.14 ± 0.05	0.08	0.44 ± 0.09	9.8	0.0002
Segment 5	0	0.33 ± 0.07	0.09	0.67 ± 0.11	18.3	0.0001
Segment 6	0	0.29 ± 0.07	0.05	0.67 ± 0.10	18.1	0.0001
Segment 10	0	0.05 ± 0.04	0.15	0.22 ± 0.07	4.5	0.05
Segment 11	0	0.09 ± 0.05	0.11	0.33 ± 0.08	6.9	0.01
Segment 12	0	0.14 ± 0.06	0.24	0.33 ± 0.08	6.2	0.01

ISSN: 1532-429X